ELMD — Electromed Inc
AMEX · Health Care · Health Care
- Latest Close
- $25.48
- 30-Day Move
- -14.4%
- Market Cap
- $193M
- Shares Outstanding
- 8,280,000
- P/E Ratio
- 21.43
- P/B Ratio
- 4.25
Electromed Inc
A read-only Alphactor snapshot forElectromed Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-23
Topline snapshot
Latest Close
$25.48
30-Day Move
-14.4%
Market Cap
$193M
Shares Outstanding
8,280,000
P/E Ratio
21.43
P/B Ratio
4.25
$25.48
-14.4%last 90 delayed daily bars
90D High
$30.73
90D Low
$23.01
Avg Volume
60,772
Gross margin is running at 78.2%, which gives a quick read on operating quality before you open the full model.
Net margin is 13.1%, useful for comparing ELMD against peers in Health Care.
ELMD is down 14.4% over the last 30 trading days shown on this page.
Latest operating income is $4M, which helps anchor the headline ratios with an actual earnings figure.
Composite Fair Value
$25.99
Rule of 40
34.3%
Latest Close
$25.48
30-Day Move
-14.4%
Market Cap
$193M
Shares Outstanding
8,280,000
P/E Ratio
21.43
P/B Ratio
4.25
ROE
17.4%
ROA
14.0%
Gross Margin
78.2%
Operating Margin
16.7%
Net Margin
13.1%
Debt / Equity
0
Current Ratio
4.31
Latest Revenue
$19M
Revenue
$19M
Gross Profit
$15M
Operating Income
$4M
Net Income
$3M
Gross Margin
7823.0%
Net Margin
1306.0%
Current Ratio
4.31
Debt / Equity
0.00
Fair Value
$25.99
Upside / Downside
+2.0%
Signal
Fairly Valued
Implied Growth
6.1%
DCF
$29.45
EPV
$8.04
EV/Rev
$40.49
Growth Assumption
15.4%
Discount Rate
10.5%
Terminal Growth
2.0%
Base FCF
$11M
Valuation spread
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Low growth priced in
Altman Z
14.02
Safe
Piotroski
7
Strong (7-9)
Cash Conversion
1.51x
Rule of 40
34.3%
Acceptable
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $42M | $3M | $2M | $-2M |
| 2023-12-31 | $48M | $4M | $3M | $-401,000 |
| 2024-12-31 | $55M | $7M | $5M | $9M |
| 2025-12-31 | $64M | $10M | $8M | $11M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
Vanguard Group
Filed 2026-01-29
$13M
+2.7%
Geode Capital Management
Filed 2026-02-09
$6M
+2.6%
Renaissance Technologies
Filed 2025-11-13
$5M
+7.3%
Two Sigma Advisers
Filed 2026-02-17
$4M
-5.1%
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Healthcare Investing: Pharma, Biotech, and the FDA Calendar
A framework for navigating healthcare stocks across pharma, biotech, and medical devices, with emphasis on regulatory catalysts and pipeline valuation.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.